PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
PharmaTher收到美国专利补贴通知，该专利涵盖治疗帕金森氏症和运动障碍的氯胺酮
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB:PHRRF) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for its "Compositions and Methods for Treating Motor Disorders" patent, intended to cover potential ketamine treatment of Parkinson's disease and motor disorders causing involuntary or uncontrollable body actions.
氯胺酮药品供应商PharmaTher控股有限公司(场外交易代码：PHRRF)已被授予一项美国专利商标局(USPTO)的补贴通知为其“治疗运动障碍的组合物和方法”申请专利，意在涵盖潜在的氯胺酮治疗帕金森病和运动障碍导致不自主的或不能控制的身体动作。
PharmaTher signed an exclusive license agreement with the University of Arizona to develop and commercialize the patent in August 2020. The results from the clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's would be made available in late-Q3 2022.
PharmaTher与该公司签署了独家许可协议亚利桑那大学在2020年8月开发该专利并将其商业化。氯胺酮治疗帕金森氏症患者左旋多巴诱导的运动障碍(LID)的临床研究结果将于2022年第三季度末公布。
More...
更...
登录免费看全文
登录/注册